Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

181. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity (Full text)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC).Outcomes of patients with NSCLC treated with nivolumab as a routine practice

2018 ESMO open PubMed

182. CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer (Full text)

CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer Lung cancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1 (...) ) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lung cancer (NSCLC) prognosis and whether these could serve as biomarkers for NSCLC detection, along with Ang-2.We prospectively studied an unselected cohort of 145 patients with NSCLC and a group of 30 control individuals. Serum levels of Ang-2 and CSF-1

2018 ESMO open PubMed

183. Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) (Full text)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC).Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab

2018 ESMO open PubMed

184. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer (Full text)

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK-positive non-small cell lung cancer. We describe patient-reported outcomes (PROs) from the NP28761 study.PROs (...) and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item EORTC QLQ-lung cancer-specific module) at enrolment and every 6 weeks until week 66, disease progression or death.Clinically meaningful mean improvements (≥10 point change from baseline) were observed in 10 domains, including global health status (GHS), role

2018 ESMO open PubMed

185. Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer (Full text)

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer This study was conducted to identify whether the presence of circulating tumor DNA (ctDNA) in plasma before treatment with EGFR-tyrosine kinase inhibitors (TKIs) is associated with clinical outcomes.Fifty-seven pairs of tissues and plasma samples were obtained from patients with NSCLC adenocarcinoma harboring activating (...) prior to disease progression.Quantitative testing can increase the sensitivity of the ctDNA detection test. Patients with detectable ctDNA had significantly shorter PFS after receiving EGFR-TKIs than those with undetectable ctDNA. Tumor burden may be associated with plasma ctDNA detection. A shorter PFS was associated with detection of ctDNA and extra-thoracic lymph node metastasis. Dynamic changes in the ctDNA level may help predict clinical outcomes.© 2018 The Authors. Thoracic Cancer published

2018 Thoracic cancer PubMed

186. Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report (Full text)

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report Squamous cancer (SqCC) of the lung has a poor prognosis. With the advent of immunotherapy, prognosis has tended to improve; however, pseudoprogression poses a challenge to the management of immunotherapy. Herein, we discuss the case of a 47-year-old heavy smoker with advanced SqCC. The patient had recurrent disease after initial successful control of the tumor by concurrent (...) for pseudoprogression. Our experience might be helpful to identify pseudoprogression for the clinical management of immunotherapy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer PubMed

187. Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer (Full text)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis.Targeted next-generation sequencing (NGS) mutation profiling (...) in PIK3CA, MET, and KRAS. Interestingly, we identified two patients with acquired mutations in the DNA mismatch repair gene POLE, which resulted in a dramatically increased tumor mutation burden, and might contribute to the poor response to crizotinib.Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.© 2018 The Authors. Thoracic Cancer published by China

2018 Thoracic cancer PubMed

188. Osimertinib (lung cancer) - Addendum to Commission A17-20

Osimertinib (lung cancer) - Addendum to Commission A17-20 1 Translation of addendum A17-47 Osimertinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-20 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-47 Version: Status: IQWiG Reports – Commission No. A17-47 (...) Osimertinib (non-small cell lung cancer) – Addendum to Commission A17-20 1 Addendum A17-47 Version 1.0 Osimertinib – Addendum to Commission A17-20 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Osimertinib (non-small cell lung cancer) – Addendum to Commission A17-20 Commissioning agency: Federal Joint Committee Commission awarded on: 12 September 2017 Internal Commission No.: A17

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

189. Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19 1 Translation of addendum A17-44 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-19 (Version 1.0; Status: 29 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 September 2017 1.0 Commission: A17-44 Version: Status: IQWiG Reports – Commission (...) No. A17-44 Alectinib (non-small cell lung cancer) – Addendum to Commission A17-19 1 Addendum A17-44 Version 1.0 Alectinib – Addendum to Commission A17-19 29 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-19 Commissioning agency: Federal Joint Committee Commission awarded on: 4 September 2017 Internal Commission

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

190. Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population

Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population To assess the performance of the Brock malignancy risk model for pulmonary nodules detected in routine clinical setting.In two academic centres in the Netherlands, we established a list of patients aged ≥40 years who received a chest CT scan between 2004 and 2012, resulting in 16 850 and 23 454 eligible subjects. Subsequent diagnosis of lung cancer until the end of 2014 was established (...) through linking with the National Cancer Registry. A nested case-control study was performed (ratio 1:3). Two observers used semiautomated software to annotate the nodules. The Brock model was separately validated on each data set using ROC analysis and compared with a solely size-based model.After the annotation process the final analysis included 177 malignant and 695 benign nodules for centre A, and 264 malignant and 710 benign nodules for centre B. The full Brock model resulted in areas under

2018 EvidenceUpdates

191. Lung cancer

Lung cancer Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

192. Atezolizumab (Tecentriq) for non?small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) for non?small cell lung cancer (NSCLC) Published 9 July 2018 1 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq ® ) SMC No 1336/18 Roche Products Limited 8 June 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end (...) of life and orphan medicine process atezolizumab (Tecentriq ® ) is accepted for restricted use within NHS Scotland Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic non -small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) -positive tumour mutations should also have received targeted therapy before receiving atezolizumab. SMC

2018 Scottish Medicines Consortium

193. Palliative thoracic radiotherapy in lung cancer

Palliative thoracic radiotherapy in lung cancer Special Article Palliative thoracic radiation therapy for non- small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation Oncology, Levine Cancer Institute (...) Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods andmaterials:BasedonasystematicPubMedsearchshowingnewevidenceforthiskey question

2018 American Society for Radiation Oncology

194. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer Crizotinib for treating R Crizotinib for treating ROS1-positiv OS1-positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer T echnology appraisal guidance Published: 4 July 2018 nice.org.uk/guidance/ta529 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 26Contents Contents 1

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

195. Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases (Full text)

Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM).Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT (...) effects, no significant difference was observed. Thus, TMZ is safe and effective.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer PubMed

196. Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer (Full text)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer 30035160 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer. 124-125 10.18632/oncoscience.416 Seguin Laetitia L INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. Féral Chloé C INSERM, U1081, CNRS, UMR7284, Institute (...) for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. eng Editorial 2018 06 23 United States Oncoscience 101636666 2331-4737 KRAS galectin-3 integrin lung cancer macropinocytosis CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 03 2018 04 05 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035160 10.18632/oncoscience.416 416 PMC6049313 Cancer Immunol Res. 2017 Mar;5(3):182-190 28108630 Nat Cell Biol. 2014 May;16(5):457

2018 Oncoscience PubMed

197. Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea (Full text)

Feasibility of an eight‐week outpatient‐based pulmonary rehabilitation program for advanced lung cancer patients undergoing cytotoxic chemotherapy in Korea The scientific evidence supporting pulmonary rehabilitation (PR) for lung cancer patients undergoing cytotoxic chemotherapy is accumulating; however, the feasibility of outpatient-based PR in these patients has not yet been evaluated in Korea. We conducted an eight-week outpatient-based PR feasibility study in a tertiary referral (...) hospital setting. Patients with advanced lung cancer (non-small cell lung cancer IIIB-IV and small-cell lung cancer extensive disease) scheduled to undergo first-line cytotoxic chemotherapy underwent PR consisting of 60-minute sessions twice a week under the guidance and supervision of a physical therapist, for a total of eight weeks. Feasibility was assessed based on completion of the PR program. In total, 12 patients (median age 68 years) were enrolled; 11 (91.7%) were male with a history of smoking

2018 Thoracic cancer PubMed

198. DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer (Full text)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer 29932513 2019 03 25 2019 03 25 1759-7714 9 8 2018 08 Thoracic cancer Thorac Cancer DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. 901-903 10.1111/1759-7714.12785 Zhu Zhongling Z Department of Clinical Pharmacology, Tianjin (...) Medical University Cancer Institute and Hospital, Tianjin, China. National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Chen Peng P National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Department of Thoracic Medical Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute

2018 Thoracic cancer PubMed

199. P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer: An updated meta‐analysis (Full text)

P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer: An updated meta‐analysis This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC).Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases. Publications relevant to P16INK4a (...) gene promoter methylation in serum or bronchoalveolar fluid/sputum were screened and included in this meta-analysis. Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated.Twenty-six publications with 1768 lung cancer cases and 1323 controls were included. The pooled sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio were 0.46 (95% confidence interval [CI] 0.43-0.48), 0.90 (95% CI 0.88-0.91), 6.33

2018 Thoracic cancer PubMed

200. Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer (Full text)

Survival rates after lobectomy versus sublobar resection for early‐stage right middle lobe non‐small cell lung cancer Lung cancer in the right middle lobe has a poorer prognosis than tumors located in other lobes. The optimal surgical procedure for early-stage non-small cell lung cancer (NSCLC) in the right middle lobe has not yet been elucidated. The aim of this study was to compare survival rates after lobectomy and sublobar resection for early-stage right middle lobe NSCLC.Patients who (...) underwent lobectomy or sublobar resection for stage IA right middle lobe NSCLC tumors ≤ 2 cm between 2004 and 2014 were identified from the Surveillance, Epidemiology and End Results database of 18 registries. Cox regression model analysis was used to evaluate the prognostic factors. The lung cancer-specific survival (LCSS) and overall survival (OS) rates between the two groups were compared.A total of 861 patients met our criteria, including 662 (76.9%) patients who underwent lobectomy and 199 (23.1

2018 Thoracic cancer PubMed